Skip to content

Effects of Implementing a High Potassium Diet in Heart Failure Patients

Safety and Physiologic Effects of Implementing a High Potassium Diet in Heart Failure Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03059680
Enrollment
30
Registered
2017-02-23
Start date
2012-01-31
Completion date
2017-01-31
Last updated
2020-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Potassium, Nutrition

Brief summary

This study evaluates the safety and physiologic effects of increasing dietary potassium intake in individuals with heart failure.

Interventions

An increase in consumption of high potassium fruits and vegetables

Sponsors

Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Treating physicians and participants were not blinded to randomization. Investigators performing randomization and analysis of dietary intake were blinded.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* All patients classified as having HF, both systolic and diastolic. * New York Heart Association class II-III symptoms. * Treatment with an beta blocker, ACE inhibitor, or angiotensin receptor blocker without any adjustment over the previous month * Intake at baseline of ≤ 3 servings of fruits and vegetables per day. Servings defined by Health Canada's food guide.

Exclusion criteria

* Patients with an episode of decompensated heart failure, acute coronary syndrome, or revascularization within the previous 3 months of study inclusion. * Patients receiving insulin therapy * Glomerular filtration rate \< 40mL/min/1.73 m2 * Pregnancy and lactation (women of childbearing potential will be included but will have to have a negative pregnancy test prior to inclusion). * Inability to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Serum potassium concentration10 days and 3 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026